



Minerva Neurosciences, Inc.  
Investor Relations Department  
1601 Trapelo Road  
Suite 284  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: NERV

Last Trade:	5.95
Trade Time:	3:56 PM ET Aug 18, 2017
Change:	-0.15  (-2.459%)
Day Range	5.85 - 6.30
52-Week Range	6.10 - 14.92
Volume	125,899

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva's proprietary compounds include: MIN-101, which has completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials for insomnia and MDD, respectively; MIN-117, which has completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Aug 3, 2017*  
[Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates](#)
- Jul 31, 2017*  
[American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia](#)
- Jul 27, 2017*  
[Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017](#)
- Jul 24, 2017*  
[Minerva Neurosciences Announces Departure of Directors](#)
- Jul 5, 2017*  
[Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares](#)

## Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)  
*Mar 13, 2017*  
[Annual Report \(10-K\)](#)
- Apr 18, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)